Criteria to qualify for study: Drug used in study:
  • R/R transfusion-independent lymphoma, newly diagnosed AML, or R/R myeloma, ECOG <2

HR 56

A phase 1a/1b dose escalation and expansion trial of TTI/-622 in patients with advanced relapsed or refractory Lymphoma or Myeloma

HR 56 Clinical Trial

Criteria to qualify for study: Drug used in study:
  • Received at least 1 prior line of therapy for AML or MDS; ECOG<2

HR 63

A Phase 1 study of NKX101, an activating chimeric receptor natural killer (ACRNK) cell therapy in subjects with hematological malignancies or dysplasia’s.

HR 63 Clinical Trial

Criteria to qualify for study: Drug used in study:
  • MDS with 5-19% blasts, HMA refractory

MDS 31

A Phase 1/2 Open-Label study of the safety, tolerability and efficacy of the selective inhibitor of Nuclear Export (SINE) Compound ELTANEXOR (KPT-8602) in patients with newly diagnosed and relapsed/refractory cancer indications.

MDS 31 Clinical Trial

Criteria to qualify for study: Drug used in study:
  • 2nd Morphological complete remission for AML; WT1 blasts

AML 56

A Randomized, Open-Label study of the efficacy and safety of Galinpepimut-S (GPS) maintenance monotherapy compared to investigator’s choice of best available therapy in subjects with Acute Myeloid Leukemia who have achieved complete remission after second line salvage therapy.

AML 56 Clinical Trial

Criteria to qualify for study: Drug used in study:
  • Newly diagnosed, untreated AML; bone marrow or peripheral blast count >20%

AML 58

SY-1425 in combination with Venetoclax and Azacitidine in adult patients with RARA-positive, previously untreated AML who are ineligible for standard induction therapy

AML 58 Clinical Trial

Criteria to qualify for study: Drug used in study:
  • Untreated AML with at least 1 TP53 mutation; ECOG < 2

AML 59

A Phase 3 randomized, open-label study evaluating the safely and efficacy of magrolimab in combination with Azacitidine versus Physicians choice of Venetoclax plus Azacitidine or intensive chemotherapy in previously untreated patients with TP53 Mutant Acute Myeloid Leukemia.

AML 59 Clinical Trial

Criteria to qualify for study: Drug used in study:
  • R/R AML after 2 cycles of therapy or newly diagnosed, unit AML; wbc <25x109/L

AML 60

A phase 1b/2, open –label, global, multicenter, dose determination, dose expansion, Umbrella study to evaluate safety, tolerability and preliminary efficacy of CC-486 (ONUREG) in combination therapy in subjects with Acute Myeloid Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (HR-MDS)

AML 60 Clinical Trial

Criteria to qualify for study: Drug used in study:
  • R/R AML or MDS with >5% blast in the marrow or any blasts in the peripheral blood; ECOG <2

AML 63

Phase 1b open label, dose-escalation and dose-expansion study of APVO436 in patients with Refractory AML or High-Grade MDS

AML 63 Clinical Trial

Criteria to qualify for study: Drug used in study:
  • R/R AML or MM

HR 70

A Phase 1 open-label, multicenter study of FT538 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in combination with Monoclonal antibodies in Relapsed/Refractory Multiple Myeloma

HR 70 Clinical Trial